Evidence map›Paper›PMID 24801134›Full record

ReviewCurrent hypertension reports2014

Hypercortisolism in obesity-associated hypertension.

Amy G Varughese, Oksana Nimkevych, Gabriel I Uwaifo

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current hypertension reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Unmasking Hormonal Mechanisms of Hypertension in Obesity.JACC. Basic to translational science · 2026
    Article
  4. Unmasking Hormonal Mechanisms of Hypertension in Obesity.medRxiv : the preprint server for health sciences · 2025
    Article
  5. Review
  6. Novel 2-(Adamantan-1-ylamino)Thiazol-4(5International journal of molecular sciences · 2021
    Article
  7. Article
  8. Review
  9. Article
  10. Cortisol dysregulation in obesity-related metabolic disorders.Current opinion in endocrinology, diabetes, and obesity · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Amy G VarugheseSection of Endocrinology, Diabetes and Metabolism, Department of Medicine, Louisiana State University Health Sciences Center (LSUHSC), 1542 Tulane Avenue, New Orleans, LA, 70112, USA, avarug@lsuhsc.edu.
Oksana Nimkevych
Gabriel I Uwaifo
Louisiana State University Health Sciences Center New Orleans · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity is prevalent worldwide and associated with co-morbidities that result in increased cardiovascular risk. Hypertension is the most prevalent obesity comorbidity associated with increased cardiovascular risk. Obesity hypertension is a distinct subtype of essential hypertension. While endogenous Cushing's syndrome is an uncommon cause of both obesity and hypertension, the recent recognition of other hypercortisolemic states has raised the profile of hypercortisolism as an important contributor in obesity hypertension. The high prevalence of exogenous, iatrogenic, pseudo, and subclinical Cushing's syndromes makes hypercortisolism an important diagnostic consideration in the evaluation and management of patients with obesity hypertension who are resistant to conventional management. Available data suggest that the renin-angiotensin-aldosterone system modulating antihypertensives have the best efficacy in hypercortisolism-mediated obesity hypertension. Strategies aimed at reducing cortisol production and action also have utility. This review provides a comprehensive overview of the epidemiology, etiopathogenesis and management options available for glucocorticoid-mediated obesity hypertension.

Indexed as

AnimalsAntihypertensive AgentsCushing SyndromeGlucocorticoidsHumansHydrocortisoneHypertensionObesityAntihypertensive AgentsGlucocorticoidsHydrocortisone

Identifiers

PMID24801134
OpenAlexW2022317647

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.